https://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1500 a year (including GST in Australia).

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

Budget 2020 Special Edition; Comment & Analysis

Mesoblast Falls 45% On FDA GvHD Trial Requirement 

Cyclopharm: US Technegas Trial Meets Endpoints Early

Dr Boreham's Crucible: Oventus Medical

Biotech Daily 1st Medical Marijuana Survey

CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims

Biotech Daily Editorial: Covid-19 Spruikers, Please Stop !

Zelira: Marijuana ZLT-101 'Effective For Insomnia'

Biotech Daily Editorial: Covid-19 Coronavirus Claims

Dr Boreham's Crucible Special: Covid-19

Biotech Daily Editorial: 2019-nCoV Coronavirus (Covid-19)

 All The Dope On Medicine, Marijuana, Cannabis & Hemp 

 


 September BDI-40 Up 1%, Big Caps Up 2.5%;
ASX200 Down 4%

Cyclopharm Up 74%, Optiscan 63%, Antisense 61%; Dimerix Down 59%

 October 1, 2020

Spring has sprung again for the Biotech Daily Top-40 Index (BDI-40), up 0.8 percent to a collective market capitalization of $16,484 million, just 1.8 percent below the January 31 all-time high of $16,788 million.
 
By comparison, the benchmark S&P ASX200 fell 4.0 percent in September to 5,816 points and 13.0 percent below September 30, 2019.
 
The BDI-40 was up 13.2 percent for the year to September 30, 2020.
 
The Nasdaq Biotechnology Index fell 0.1 percent in September but was up 36.1 percent for the year.
 
The collective market capitalization of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed 2.5 percent in September, up 24.25 percent for the year.
 
CSL climbed $4,497 million or 3.5 percent to $134,457 million with Cochlear up 5.5 percent to $13,325 million. Resmed slipped a further 1.9 percent to $34,346 million.
 
In September, 21 of the BDI-40 companies were up, 13 by more than 10 percent and three by more than 60 percent. Nineteen fell, with nine down by more than 10 percent and two down by more than 20 percent.
 
Cyclopharm was the best, following its US phase III Technegas lung imaging trial meeting its primary efficacy endpoint, up $82 million or 73.9 percent to $193 million.
 
From a lower base, Optiscan was up 63.3 percent to $49 million, followed by Antisense (61.4%), Immutep (28.4%), Amplia (26.7%), Patrys (23.5%), Prescient (18.9%), Resonance (17.7%), Clinuvel (17.3%), Cynata (16.3%), Oncosil (13.7%), Opthea (11.1%) and Compumedics (10.1%).
 
Dimerix led the falls, following DMX-200 for diabetic kidney disease not meeting its phase II primary endpoint, down $86 million or 58.9 percent to $60 million.
 
Genetic Signatures continuing to ease from its July high, down 24.9 percent to $244 million, followed by Imugene (14.5%), Proteomics (14.3%), Neuren (13.0%), Kazia (12.5%), Medical Developments (11.1%), Universal Biosensors (10.9%) and Pharmaxis (10.5%).
 
Cannabis Corner was up 10.5 percent in August to $1,266 million, but down 33.9 percent for the year to September 30.
 
On the Nasdaq, Redhill (with Australian assets) was up 34.9 percent to $533 million on the continuation of its trial of opaganib, or Yeliva, for Covid-19, while Queensland’s Protagonist eased 10.2 percent to $1,004 million, and Eyepoint (Psivida) was unchanged at $91 million.
 
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Sep 30, 2020 
 
 
5-Year Big Caps (Cochlear, CSL, Resmed) to Sep 30, 2020


BDI-40 ($m) v S&P ASX200 – Year to Sep 30, 2020 
(current, raw data)
 

  

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At September 30, 2020

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear
   Cynata, Mesoblast, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: 
   https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/